Zepbound vs. Wegovy: Which Is Better? Side-by-Side Comparison​

If your main goal is to lose as much weight as possible, Zepbound is generally the better choice. In a clinical trial directly comparing both medications, Zepbound produced significantly greater average weight loss than Wegovy after 72 weeks.

However, if you have established cardiovascular disease and obesity or overweight, Wegovy may be the better option because it has an FDA-approved indication for reducing the risk of major cardiovascular events in these patients. Wegovy also offers an oral tablet option for eligible adults who prefer not to use injections.

So, which one should you choose? It depends on your medical history and what you’re trying to accomplish. Zepbound contains tirzepatide, while Wegovy contains semaglutide. Both regulate appetite, but Zepbound targets two hormone receptors instead of one.

Ultimately, Zepbound has the advantage in average weight loss, while Wegovy offers additional approved benefits for certain cardiovascular and liver conditions. The best choice depends on which medication addresses your health priorities while being safe and appropriate for your individual needs.

DFWPMA offers GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications to eligible patients when medically appropriate, subject to medication availability.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is Zepbound?

Zepbound (tirzepatide) is a prescription medication approved for chronic weight management in adults with obesity or overweight with at least one weight-related medical condition. It is also FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity.

Zepbound activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action helps regulate appetite, reduce food intake, and promote substantial weight loss. Although tirzepatide also improves blood sugar regulation, Zepbound is not specifically FDA-approved to treat type 2 diabetes.

What Is Wegovy?

Wegovy (semaglutide) is a prescription GLP-1 receptor agonist approved for chronic weight management in adults with obesity or qualifying overweight and adolescents aged 12 years and older with obesity, using the injectable formulation. It is also approved to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

Wegovy works by activating GLP-1 receptors, which regulate appetite, increase feelings of fullness, and reduce food intake. Unlike Zepbound, Wegovy is available in both injectable and oral formulations, although their approved populations and indications differ. 

Wegovy injection also has an accelerated FDA approval for treating certain adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

Wegovy

Zepbound vs. Wegovy: Side by Side Comparison

Zepbound and Wegovy differ primarily in their active ingredients, weight-loss effectiveness, approved medical uses, and administration options. Zepbound produced greater average weight loss than injectable Wegovy in a direct clinical trial, while Wegovy has additional cardiovascular and liver-related indications and an oral formulation. Both require medical evaluation and ongoing monitoring.

ComparisonZepboundWegovy
ManufacturerEli Lilly and CompanyNovo Nordisk
Pricing

Manufacturer self-pay options:

  • Starting Price: $299/month for the 2.5 mg starting dose through eligible manufacturer self-pay options.
  • Higher Doses: Approximately $399–$449/month under qualifying self-pay programs, depending on dosage and refill requirements.
  • Eligibility: Pricing depends on delivery device, dosage, and manufacturer program requirements.

Retail prices may be higher.

Manufacturer self-pay offers:

  • Introductory Offer: Starting at $199/month for eligible new injection patients during a limited promotional period.
  • Standard Injection Offers: Approximately $349/month for standard injection doses through eligible programs.
  • Oral Formulation: Self-pay offers starting at $149/month, with higher costs for certain doses.

Retail prices may be higher.

Insurance Coverage
  • Commercial Insurance: Some plans cover Zepbound for eligible patients with obesity or other approved indications.
  • Prior Authorization: Medical eligibility and documentation may be required.
  • Medicare: Coverage depends on the approved indication, applicable program rules, and individual plan.
  • Commercial Insurance: Some plans cover Wegovy for qualifying weight-management or other approved indications.
  • Medicare Part D: Coverage may be available for certain medically eligible patients under approved indications and applicable rules.
  • Prior Authorization: Coverage may require documentation of cardiovascular disease, obesity, or other qualifying conditions.
Main PurposeLong-term weight loss and weight maintenance in eligible adults with obesity or overweight.Long-term weight loss and weight maintenance in eligible adults, with injectable treatment also approved for adolescents aged 12 years and older with obesity.
Secondary Purposes
  • Sleep Apnea: Treat moderate to severe obstructive sleep apnea in adults with obesity.
  • Metabolic Health: May improve blood sugar regulation and other metabolic measures.
  • Cardiovascular Protection: Reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
  • Liver Disease: Wegovy injection treats certain adults with noncirrhotic MASH and moderate to advanced liver fibrosis under accelerated approval.
Active IngredientTirzepatide, a dual GIP and GLP-1 receptor agonist.Semaglutide, a GLP-1 receptor agonist.
Benefits
  • Weight Loss: Produces substantial average weight reduction, exceeding injectable Wegovy in a direct clinical trial.
  • Appetite Regulation: Reduces hunger and food intake.
  • Metabolic Health: May improve weight-related metabolic measures.
  • Sleep Apnea: Reduces obstructive sleep apnea severity in eligible adults with obesity.
  • Weight Management: Produces clinically meaningful weight loss and helps maintain weight reduction.
  • Cardiovascular Health: Reduces major cardiovascular events in eligible adults with established cardiovascular disease.
  • Liver Health: Wegovy injection may improve MASH and liver fibrosis in qualifying adults.
  • Administration Options: Offers injectable and oral formulations for eligible patients.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Gastrointestinal Reactions: Potentially severe digestive symptoms.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Possible worsening of diabetic retinopathy in patients with diabetes.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
Weight Loss PotentialApproximately 20.2% average body-weight reduction after 72 weeks in the SURMOUNT-5 head-to-head trial involving adults with obesity or qualifying overweight without diabetes. Zepbound produced greater average weight loss than injectable Wegovy under the conditions studied.Approximately 13.7% average body-weight reduction after 72 weeks in the same SURMOUNT-5 trial. Wegovy remains an effective weight-management treatment, although average weight loss was lower than Zepbound in this comparison. Results vary by dosage, formulation, and patient characteristics.
Administration
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Available Forms: Different injection devices and vial presentations.
  • Injection: Subcutaneous injection once weekly.
  • Oral Tablet: Once-daily oral formulation with specific administration instructions.
  • Injection Sites: Abdomen, thigh, or upper arm.
Dosing Considerations
  • Starting Dose: Typically 2.5 mg weekly.
  • Dose Escalation: Gradual increases according to response and tolerability.
  • Maintenance Dose: Usually 5 mg, 10 mg, or 15 mg weekly for weight management.
  • Starting Injection Dose: Typically 0.25 mg weekly.
  • Dose Escalation: Gradual increases, with 2.4 mg weekly the usual recommended injection maintenance dose for weight management.
  • Oral Dosing: Starts at 1.5 mg daily and increases according to a separate schedule, with 25 mg daily the recommended maintenance dose.
Who May Benefit Most?Adults with obesity or qualifying overweight who prioritize greater average weight loss, including eligible patients with obesity-related moderate to severe obstructive sleep apnea.Adults with obesity or qualifying overweight who also have established cardiovascular disease, eligible adults with MASH, and patients who may benefit from an oral formulation. Wegovy injection may also benefit adolescents aged 12 years and older with obesity.
How Fast Does It Work?
  • Appetite: Changes may begin within the first several weeks.
  • Initial Weight Loss: May become noticeable within several weeks.
  • Substantial Weight Loss: Generally develops over several months, with the SURMOUNT-5 trial assessing outcomes at 72 weeks.
  • Appetite: Changes may begin within the first several weeks.
  • Initial Weight Loss: May become noticeable within several weeks.
  • Substantial Weight Loss: Typically develops gradually over several months, with clinical trials assessing outcomes over extended treatment periods.
Potential Side Effects
  • Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
  • Other Effects: Fatigue and injection-site reactions.
  • Timing: Gastrointestinal symptoms frequently occur during dose escalation.
  • Digestive: Nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion.
  • Other Effects: Headache, fatigue, and possible injection-site reactions with injectable treatment.
  • Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.

Information Accuracy Disclaimer: Pricing, insurance coverage, medication availability, and other details may change over time. The information presented in this comparison reflects available information as of November 9, 2026. For the most current details, consult the medication manufacturers, your insurance provider, or a qualified healthcare professional.

Important: Both medications carry a boxed warning concerning thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown. Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). 

Zepbound and Wegovy should not be used together because combining GLP-1-based therapies is not recommended. Treatment selection requires an individualized medical assessment.

Weight-loss evidence: In the SURMOUNT-5 clinical trial, Zepbound (tirzepatide) produced an average 20.2% body-weight reduction compared with 13.7% for Wegovy (semaglutide) after 72 weeks in adults with obesity or overweight and at least one weight-related medical condition, without diabetes.

 This represents approximately 47% greater relative weight loss with Zepbound. The study directly compared the injectable formulations at maximum tolerated doses, so its findings should not be automatically applied to Wegovy’s oral formulation or other dosing regimens.

Sources:

Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of Zepbound and Wegovy. It is not a substitute for professional medical advice, diagnosis, or treatment.

The safety, effectiveness, and suitability of either medication depend on individual medical history, health conditions, and treatment goals. For a comprehensive evaluation and personalized treatment recommendations, consult a qualified healthcare provider before starting, changing, or discontinuing either medication.